World's Best Scientists 2026 revealed!
Beatriz Grinsztejn

Beatriz Grinsztejn

Award Badge
Microbiology
Brazil
2026

D-Index & Metrics

Microbiology

D-Index
76
Citations
31951
World Ranking
1384
National Ranking
7

Research.com Recognitions

  • 2026 - Research.com Microbiology in Brazil Leader Award

Overview

Beatriz Grinsztejn is affiliated with the Oswaldo Cruz Foundation in Brazil. Their research primarily spans the field of Medicine, with a particular focus on Infectious Diseases, Epidemiology, and Virology. Additional areas of interest include Sociology and Political Science as well as Emergency Medicine.

Their work addresses a variety of major topics including HIV/AIDS Research and Interventions, HIV Research and Treatment, and HIV, Drug Use, Sexual Risk. Other key topics within their scientific scope are HIV/AIDS drug development and treatment, SARS-CoV-2 and COVID-19 Research, issues related to sex work, and HIV-related health complications and treatments.

Grinsztejn has contributed to scholarly literature in numerous journals and platforms. Frequent publication venues include:

  • UNC Libraries
  • Journal of the International AIDS Society
  • The Brazilian Journal of Infectious Diseases
  • AIDS and Behavior
  • The Lancet Regional Health - Americas

The scientist has collaborated regularly with several researchers over the years. Frequent co-authors include:

  • Valdiléa G. Veloso
  • Sandra Wagner Cardoso
  • Thiago S. Torres
  • Brenda Hoagland
  • Emília M. Jalil

Selected recent papers by Grinsztejn feature contributions to prominent journals and cover topics related to infectious diseases and HIV research. Notable publications include:

  • "Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19," 2021, New England Journal of Medicine
  • "Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women," 2021, New England Journal of Medicine
  • "Mpox in people with advanced HIV infection: a global case series," 2023, The Lancet
  • "Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S," 2022, New England Journal of Medicine
  • "A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19," 2021, Journal of Clinical Investigation

Best Publications

  • Prevention of HIV-1 Infection with Early Antiretroviral Therapy

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • Antiretroviral Therapy for the Prevention of HIV-1 Transmission

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Raphael J Landovitz;Deborah Donnell;Meredith E Clement;Brett Hanscom

  • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

    Beatriz Grinsztejn;Bach Yen Nguyen;Christine Katlama;Jose M. Gatell

  • Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

    Beatriz Grinsztejn;Mina C. Hosseinipour;Heather J. Ribaudo;Susan Swindells

  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

    Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

    Pedro Cahn;Anton L Pozniak;Horacio Mingrone;Andrey Shuldyakov

  • What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)

    Steven M. Goodreau;Nicole Bohme Carnegie;Eric Vittinghoff;Javier R. Lama

  • Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis

    Nathan Ford;Zara Shubber;Graeme Meintjes;Beatriz Grinsztejn

  • Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

    Margaret Johnson;Beatriz Grinsztejn;Claudia Rodriguez;Jeffrey Coco

  • 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

    Margaret Johnson;Beatriz Grinsztejn;Claudia Rodriguez;Jeffrey Coco

  • Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection

    Karin Nielsen-Saines;D. Heather Watts;Valdilea G. Veloso;Yvonne J. Bryson

  • Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

    Christine Katlama;Roberto Esposito;Jose M Gatell;Jean-Christophe Goffard

  • Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study

    Beatriz Grinsztejn;Brenda Hoagland;Ronaldo I Moreira;Esper G Kallas

  • The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

    F. Van Leth;S. Andrews;B. Grinsztejn;E. Wilkins

  • Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

    Calvin J. Cohen;Jean-Michel Molina;Pedro Cahn;Bonaventura Clotet

  • Unveiling of HIV dynamics among transgender women: a respondent-driven sampling study in Rio de Janeiro, Brazil

    Beatriz Grinsztejn;Emilia M Jalil;Laylla Monteiro;Luciane Velasque

  • Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.

    David R Bakal;Lara E Coelho;Paula M Luz;Jesse L Clark

  • Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1–Infected Women

    Erna Milunka Kojic;Minhee Kang;Michelle S. Cespedes;Triin Umbleja

  • TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis

    Nathan Ford;Alberto Matteelli;Alberto Matteelli;Zara Shubber;Sabine Hermans;Sabine Hermans

  • The future role of CD4 cell count for monitoring antiretroviral therapy

    Nathan Ford;Nathan Ford;Graeme Meintjes;Anton Pozniak;Helen Bygrave

  • Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

    Raphael J. Landovitz;Sue Li;Beatriz Grinsztejn;Halima Dawood

  • Changing Mortality Profile among HIV-Infected Patients in Rio de Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in the HAART Era

    Beatriz Grinsztejn;Paula M. Luz;Antonio G. Pacheco;Desiree V. G. Santos

  • HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel.

    Jeanne M. Marrazzo;Carlos del Rio;David R. Holtgrave;Myron S. Cohen

  • Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

    Thomas B. Campbell;Laura M. Smeaton;N. Kumarasamy;Timothy Flanigan

Frequent Co-Authors

Paula M. Luz
Paula M. Luz Oswaldo Cruz Foundation
Pedro Cahn
Pedro Cahn University of Buenos Aires
Kenneth H. Mayer
Kenneth H. Mayer Harvard Medical School
Myron S. Cohen
Myron S. Cohen University of North Carolina at Chapel Hill
Susan H. Eshleman
Susan H. Eshleman Johns Hopkins University School of Medicine
Eduardo Gotuzzo
Eduardo Gotuzzo Instituto de Medicina Tropical Alexander von Humboldt
Judith S. Currier
Judith S. Currier University of California, Los Angeles
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Joseph Makhema
Joseph Makhema Harvard University
Jean-Michel Molina
Jean-Michel Molina Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Microbiology opens doors to diverse career opportunities, many of which can be enhanced through related online degrees. For those with a complex background, it’s encouraging to note that the best degree for felons options include programs that offer flexibility and a fresh start in scientific and healthcare fields.

Healthcare-related pathways often align well with microbiology studies. For example, becoming a functional medicine nurse practitioner can be a fulfilling career choice, blending microbiological science with holistic patient care. This role requires specialized knowledge that can be pursued through online education and certification programs.

Alternatively, careers in medical coding and health information are also accessible to microbiology graduates. Understanding the cpc salary landscape demonstrates that certified professional coders have promising earning potential and job stability, making it a compelling option for those interested in healthcare administration.

Similarly, learning about health information management salary entry-level roles highlights opportunities in managing patient data and healthcare systems, careers that complement microbiological knowledge with information technology and management skills.

Best Scientists Citing Beatriz Grinsztejn

Trending Scientists

Recently Published Articles